Hui Deng

Title: Innovations of Inventor Hui Deng

Introduction

Hui Deng is a notable inventor based in Houston, TX (US), recognized for his contributions to the field of biotechnology. He holds 2 patents that focus on advancements in cancer treatment and chemotherapy sensitivity.

Latest Patents

Hui Deng's latest patents include "Monoclonal antibodies against endotrophin and the use thereof." This invention relates to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. The method involves administering an effective amount of an endotrophin-neutralizing agent to patients in need. The agent can be a monoclonal antibody or a fragment capable of binding to the C5 domain of the alpha chain of collagen VI. Additionally, the method may include administering an effective amount of thiazolidinedione to enhance treatment efficacy. Another significant patent is "DDR1 antibodies and uses thereof," which pertains to antibodies that bind to tumor discoidin domain receptor 1 (DDR1) and their applications in detecting and treating cancer.

Career Highlights

Hui Deng has worked with prestigious institutions, including the University of Texas System and Washington University. His work has significantly impacted the development of innovative therapies in oncology.

Collaborations

Hui has collaborated with notable colleagues, including Ningyan Zhang and Zhiqiang An, contributing to advancements in his field.

Conclusion

Hui Deng's innovative work in biotechnology and cancer treatment exemplifies the importance of research and development in improving patient outcomes. His patents reflect a commitment to enhancing therapeutic strategies in oncology.